Hydrocortisone - topical

Classification: B

Drug products: Cortimyk, Daktacort®, Fenuril®-Hydrokortison, Ficortril®, Fucidin®-Hydrocortison, Fucidin-Hydrocortison, Fusidinsyra/Hydrokortison 2care4, Hydrokortison Apofri, Hydrokortison Evolan, Hydrokortison PharmSwed, Hydrokortison-svavel i Essex kräm APL, Locoid, Locoid Crelo, Locoid Lipid, Locoid®, Mildison Lipid, Softacort, Terracortril med polymyxin B, Terracortril med Polymyxin B, Terra-Cortril med polymyxin B, Terracortril®, Terracortril® med Polymyxin B, Uniderm®, Xerclear, Zoviduo

ATC code: D01AC20, D06BB53, D07AA02, D07AB02, D07CA01, D07XA01, S01BA02, S03CA04

Summary

Controlled studies on differences between men and women regarding efficacy, safety and pharmacokinetics of topical hydrocortisone are lacking.

The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.

Additional information

Pharmacokinetics and dosing

No studies with a clinical relevant sex analysis regarding the pharmacokinetics or dosing of topical hydrocortisone have been found.

Effects

No studies with a clinical relevant sex analysis regarding the effects of topical hydrocortisone have been found.

Adverse effects

No studies with a clinical relevant sex analysis regarding the adverse effects of topical hydrocortisone have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2020-08-28

Date of litterature search: 2015-11-27

References

Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.] länk
Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.] länk

Authors: Maria Enghag, Desirée Loikas

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson